We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01433497
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : April 8, 2020
Sponsor:
Information provided by (Responsible Party):
AB Science

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Relapse Free Drug: Masitinib Drug: Placebo Phase 3

Detailed Description:
Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day versus matched placebo, or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after 3 months of treatment versus matched placebo, in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis. Approximately 600 patients will be randomized into four treatment groups with a 2:2:1:1 design. The primary outcome measure is the Expanded Disability Status Scale (EDSS) after 96 weeks of treatment in the overall study population with subgroup analysis performed in stratum (primary progressive multiple sclerosis / secondary progressive multiple sclerosis).
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 656 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Actual Study Start Date : August 2011
Actual Primary Completion Date : September 2019
Actual Study Completion Date : February 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Experimental Arm A
Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
 Drug: Masitinib
Other Name: AB1010
Experimental: Experimental Arm B
Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
 Drug: Masitinib
Other Name: AB1010
Placebo Comparator: Placebo Comparator A
Participants receive placebo given orally twice daily.
 Drug: Placebo
Other Name: Placebo Oral Tablet
Placebo Comparator: Placebo Comparator B
Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
 Drug: Placebo
Other Name: Placebo Oral Tablet


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. EDSS [ Time Frame: 96 weeks ]
    Expanded Disability Status Scale (EDSS) after 96 weeks of treatment


Secondary Outcome Measures :
  1. MSQOL-54 [ Time Frame: 96 weeks ]
    Multiple Sclerosis Quality of Life 54 items (MSQOL-54)

  2. MSFC [ Time Frame: 96 weeks ]
    Multiple Sclerosis Functional Composite (MSFC)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main inclusion criteria:

- Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald's criteria.

Main exclusion criteria:

- Patient suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433497


Locations
Layout table for location information
Bulgaria
"St. Ivan Rilski" University Multiprofile Hospital for Active Treatment
Sofia, Bulgaria, 1431
France
GHICL hopital ST vincent de Paul
Lille, France, 59020
Hôpital de Gui de Chauliac
Montpellier, France, 34295
Germany
Universitätsklinikum Gießen und Marburg
Marburg, Germany, D-35033
Greece
Rehibilitation Center "KENTAVROS"
Volos, Greece, 382 21
Poland
KO-MED Centra Kliniczne Lublin II
Lublin, Poland, 20-362
Romania
Centrul Medical Clubul Sănătăţii
Campulung, Romania, 115100
Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041
Sponsors and Collaborators
AB Science
Investigators
Layout table for investigator information
Principal Investigator: Patrick Vermersch, MD, PhD Hôpital Salengro, Lille, France
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: AB Science
ClinicalTrials.gov Identifier: NCT01433497    
Other Study ID Numbers: AB07002
First Posted: September 14, 2011    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: April 2020
Keywords provided by AB Science:
multiple sclerosis
primary progressive
relapse-free
secondary progressive
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
Recurrence
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Neoplastic Processes
Neoplasms
Disease Attributes